Understand Your Clinical Trial Patients—Deeply
Many trials fall short because patient heterogeneity isn’t fully understood. Magellan reveals the molecular patterns that define response, variability, and outcome—using samples most sponsors already collect. Our analytical tools analyze every detected biomolecule in an unbiased way -- identifying novel patterns that inform better clinical development decisions.
The Problem: Not Fully Understanding Trial Participants
Most clinical trials entail significant uncertainty:
-
Patient populations are heterogeneous
-
Response signals are often diluted or missed
-
Critical biological differences remain hidden
When patients aren't clearly understood, trial outcomes become unpredictable
Why Current Approaches Fall Short
Modern approaches to understanding patients rely on incomplete views of biology.
Whether based on targeted assays, predefined biomarkers, or constrained datasets, most methods:
-
Capture only a small fraction of the biological information present in a sample
-
Focus on what markers are already expected or known
-
Lack the depth needed to fully differentiate complex patient populations
As a result:
-
Important biological differences between patients remain unresolved
-
Subtle but meaningful signals are missed
-
Patient stratification is often incomplete or imprecise
When the underlying data lacks depth, the decisions it informs are inherently limited.
Blood as a Source of Patient Information
In theory, using mass spectrometry to analyze blood samples should be one of the most powerful ways to understand patients. However, in practice, that potential is rarely realized.
The limitation is not the sample or the instrument—but in the ability to process the data. Mass spectrometry generates data at a scale traditional software cannot handle.
As a result, researchers must:
-
Simplify sample preparation to limit the number of detectable molecules
-
Adjust instrument methods to reduce data complexity
-
Pre-select or filter data before analysis, and/or
-
Focus on known or expected molecular targets
These decisions are not driven by biology—they are driven by computational limitations.
Blood contains deep patient information—but most workflows capture only part of it.
How Magellan is Fundamentally Different
Magellan removes this constraint at its source.
Our research technology, COMPASS, is designed to process the full scale and complexity of mass spectrometry data—without requiring reduction, filtering, or pre-selection.
Because of this, the entire workflow changes:
-
Samples can be prepared to release the broadest possible range of molecular information
-
Instruments can be run to capture all detectable signals
-
All resulting data can be retained and analyzed in full
By removing computational constraints, the full biology becomes visible.
What This Enables
By removing computational bottlenecks, Magellan:
-
Fully leverages the informational richness of blood
-
Utilizes the complete capability of mass spectrometry
-
Eliminates bias introduced through data reduction and pre-selection
-
Achieves a level of biological depth and resolution not accessible through conventional approaches
A deeper view of patient biology reveals meaningful differences between patients.
Magellan is Designed to Help You:
-
Identify treatment-response signals
-
Stratify patients
-
Detect clinically relevant subgroups
-
Inform enrollment and trial design decisions
Make better-informed decisions about your patients and your trial.
How It Fits Into Your Trial
Using standard serum or plasma samples, Magellan integrates into existing studies without changing workflows.
-
No specialized sample collection required
-
Applicable to retrospective or prospective studies
-
Scales from pilot work to large trials
Works with prospective or banked serum or plasma samples—no additional collection required.